Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.49 |
| ▸ | CA1 | P00915 | 7/20 | 0.49 |
| ▸ | CA2 | P00918 | 7/20 | 0.49 |
| ▸ | CA9 | Q16790 | 7/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888006 | 0.93 | TDP1 (0.53) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL28980953 | 0.90 | CA12 (0.57) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL12259524 | 0.88 | IDO1 (0.49) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL7479664 | 0.88 | TDP1 (0.49) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL2152898 | 0.87 | TDP1 (0.51) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL18354701 | 0.86 | TDP1 (0.50) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL8274545 | 0.85 | IDO1 (0.55) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL1877046 | 0.85 | TDP1 (0.46) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL8005989 | 0.84 | CA12 (0.49) | IDO1MEN1GAAKMT2ATDP1 | |
| SCHEMBL28133475 | 0.84 | TDP1 (0.53) | IDO1MEN1GAAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251158-A1 | FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE | LUNA INNOVATIONS INCORPORATED (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251158-A1 | FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE | IL1B, IL1A, CD68 | IDO1 3263/4885MEN1 1844/4885GAA 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.